4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a research report issued on Tuesday,Weiss Ratings reports.
A number of other analysts have also recently commented on the company. Chardan Capital lowered their price target on 4D Molecular Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Bank of America lowered their target price on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a research note on Monday, March 10th. Morgan Stanley reduced their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating on the stock in a research report on Monday, January 13th. BMO Capital Markets downgraded 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. Finally, Royal Bank of Canada reduced their target price on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $26.71.
Check Out Our Latest Analysis on 4D Molecular Therapeutics
4D Molecular Therapeutics Trading Up 1.5 %
Shares of NASDAQ:FDMT traded up $0.04 during trading on Tuesday, hitting $2.63. 822,218 shares of the company's stock were exchanged, compared to its average volume of 829,065. The firm has a market cap of $121.77 million, a P/E ratio of -0.92 and a beta of 2.89. The firm has a 50-day moving average price of $4.04 and a two-hundred day moving average price of $6.09. 4D Molecular Therapeutics has a 1-year low of $2.24 and a 1-year high of $28.93.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10). As a group, research analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.
Institutional Trading of 4D Molecular Therapeutics
A number of institutional investors have recently made changes to their positions in the business. Decheng Capital LLC increased its stake in 4D Molecular Therapeutics by 0.5% in the 4th quarter. Decheng Capital LLC now owns 400,000 shares of the company's stock valued at $2,228,000 after buying an additional 2,165 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in 4D Molecular Therapeutics by 7.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company's stock worth $247,000 after acquiring an additional 2,925 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in 4D Molecular Therapeutics by 66.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock valued at $51,000 after purchasing an additional 3,630 shares during the last quarter. Rhumbline Advisers grew its stake in 4D Molecular Therapeutics by 5.3% in the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock valued at $409,000 after purchasing an additional 3,675 shares in the last quarter. Finally, ProShare Advisors LLC increased its position in shares of 4D Molecular Therapeutics by 30.1% during the 4th quarter. ProShare Advisors LLC now owns 16,369 shares of the company's stock worth $91,000 after purchasing an additional 3,783 shares during the last quarter. Institutional investors own 99.27% of the company's stock.
4D Molecular Therapeutics Company Profile
(
Get Free Report)
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
See Also
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
